VOICED : Cuba prueba en Italia eficacia de su vacuna anticovid para convalecientes

Cuba is testing its COVID-19 vaccine, Soberana Plus, aimed at recovering patients. BioCuba Pharma reports strong neutralization against beta and delta variants in Italian trials. Soberana Plus is a single-dose vaccine and a booster after two doses of Soberana 2. Another vaccine, Abdala, is also developed in Cuba. All Cuban vaccines await WHO approval and are based on a SARS-CoV-2 protein. They claim over 90% efficacy in preventing symptomatic disease. Cuba has vaccinated 55.8% of its population with its vaccines.

What is the primary target group for the Soberana Plus vaccine?

• Convalescent COVID-19 patients

• Children under 12

• Elderly population

• Healthcare workers

Which country is conducting studies on the Soberana Plus vaccine?

• Brazil

• Italy

• Mexico

• Spain

What is the role of Soberana Plus in the vaccination regimen?

• First dose

• Not used in vaccination

• Single dose and booster

• Second dose

Which organization is Cuba awaiting approval from for its vaccines?

• FDA

• CDC

• WHO

• EMA

What is the claimed efficacy of Cuban vaccines in preventing symptomatic COVID-19?

• 95%

• 90%

• 80%

• 70%